MX2021014473A - Compuestos y metodos dirigidos a la tau humana. - Google Patents

Compuestos y metodos dirigidos a la tau humana.

Info

Publication number
MX2021014473A
MX2021014473A MX2021014473A MX2021014473A MX2021014473A MX 2021014473 A MX2021014473 A MX 2021014473A MX 2021014473 A MX2021014473 A MX 2021014473A MX 2021014473 A MX2021014473 A MX 2021014473A MX 2021014473 A MX2021014473 A MX 2021014473A
Authority
MX
Mexico
Prior art keywords
human tau
compounds
targeting human
methods targeting
tau
Prior art date
Application number
MX2021014473A
Other languages
English (en)
Inventor
David Albert Driver
Xiyun Chai
Jinbiao Chen
Jeffrey L Dage
Steven Fisher Hinton
Ii Robert William Siegel
Peter Edward Vaillancourt
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MX2021014473A publication Critical patent/MX2021014473A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Neurosurgery (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invención proporciona compuestos y métodos dirigidos a tau humana, particularmente tau humana fosforilada en la treonina 217 e isoformas de tau expresadas solo en el SNC, incluidos anticuerpos terapéuticos, composiciones farmacéuticas y aplicaciones de diagnóstico útiles en el campo de enfermedades neurodegenerativas tales como AD, PSP y FTD.
MX2021014473A 2019-05-31 2020-05-22 Compuestos y metodos dirigidos a la tau humana. MX2021014473A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962855331P 2019-05-31 2019-05-31
PCT/US2020/034274 WO2020242963A1 (en) 2019-05-31 2020-05-22 Compounds and methods targeting human tau

Publications (1)

Publication Number Publication Date
MX2021014473A true MX2021014473A (es) 2022-01-06

Family

ID=71083730

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021014473A MX2021014473A (es) 2019-05-31 2020-05-22 Compuestos y metodos dirigidos a la tau humana.

Country Status (12)

Country Link
US (1) US20220146535A1 (es)
EP (1) EP3977135A1 (es)
JP (2) JP7291250B2 (es)
KR (2) KR102633666B1 (es)
CN (1) CN113950625A (es)
AU (2) AU2020283534B2 (es)
BR (1) BR112021021062A2 (es)
CA (1) CA3140201A1 (es)
EA (1) EA202192888A1 (es)
IL (1) IL287611A (es)
MX (1) MX2021014473A (es)
WO (1) WO2020242963A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024503025A (ja) 2021-01-11 2024-01-24 イーライ リリー アンド カンパニー 抗Ｎ３ｐＧｌｕアミロイドベータ抗体及びその使用
TW202300518A (zh) 2021-03-12 2023-01-01 美商美國禮來大藥廠 抗N3pGlu類澱粉β抗體及其用途
TW202300517A (zh) 2021-03-12 2023-01-01 美商美國禮來大藥廠 抗類澱粉β抗體及其用途
WO2022251048A1 (en) 2021-05-24 2022-12-01 Eli Lilly And Company Anti-amyloid beta antibodies and uses thereof
IL312045A (en) 2021-10-22 2024-06-01 Lilly Co Eli Combination therapy with O-GLCNACASE (OGA) inhibitors.
WO2023076970A1 (en) 2021-10-29 2023-05-04 Eli Lilly And Company Compounds and methods targeting interleukin-34
WO2023076971A1 (en) 2021-10-29 2023-05-04 Eli Lilly Company Compounds and methods targeting interleukin-34
AU2022379194A1 (en) 2021-10-29 2024-05-02 Eli Lilly And Company Compounds and methods targeting interleukin-34
IL312380A (en) 2021-10-29 2024-06-01 Lilly Co Eli Compounds and methods targeting interleukin-34
CN117003863A (zh) * 2022-04-28 2023-11-07 厦门大学 针对p-tau 217的抗体及其用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998022120A1 (en) * 1996-11-19 1998-05-28 The Wistar Institute Of Anatomy & Biology Diagnostic and therapeutic reagents for alzheimer's disease
ATE342509T1 (de) * 2000-01-24 2006-11-15 Innogenetics Nv Diagnose von tauopathien durch bestimmung des verhältnisses von tau/phospho-tau
WO2008140639A2 (en) * 2007-02-08 2008-11-20 Oligomerix, Inc. Biomarkers and assays for alzheimer's disease
MY183989A (en) * 2011-09-19 2021-03-17 Axon Neuroscience Se Protein-based therapy and diagnosis of tau-mediated pathology in alzheimer's disease
WO2014011972A1 (en) 2012-07-13 2014-01-16 Bristol-Myers Squibb Company Tau immunoassay
KR101696061B1 (ko) * 2015-03-05 2017-01-13 재단법인 아산사회복지재단 퇴행성 뇌질환 진단에 적합한 이미지 바이오 마커를 획득하는 방법, 장치 및 이를 이용하여 퇴행성 뇌질환을 진단하는 방법
WO2018152359A1 (en) 2017-02-17 2018-08-23 Denali Therapeutics Inc. Anti-tau antibodies and methods of use thereof
JOP20180021A1 (ar) 2017-03-16 2019-01-30 Janssen Biotech Inc الأجسام المضادة لتكتلات خيوط بروتين تاو (tau) الحلزونية المزدوجة واستخداماتها

Also Published As

Publication number Publication date
JP7291250B2 (ja) 2023-06-14
CN113950625A (zh) 2022-01-18
WO2020242963A1 (en) 2020-12-03
EA202192888A1 (ru) 2022-03-23
AU2020283534A1 (en) 2021-11-25
EP3977135A1 (en) 2022-04-06
US20220146535A1 (en) 2022-05-12
JP2023110033A (ja) 2023-08-08
KR102633666B1 (ko) 2024-02-06
CA3140201A1 (en) 2020-12-03
AU2024203048A1 (en) 2024-05-30
JP2022534759A (ja) 2022-08-03
AU2020283534B2 (en) 2024-05-16
IL287611A (en) 2021-12-01
KR20240019394A (ko) 2024-02-14
KR20220004118A (ko) 2022-01-11
BR112021021062A2 (pt) 2021-12-14

Similar Documents

Publication Publication Date Title
MX2021014473A (es) Compuestos y metodos dirigidos a la tau humana.
PH12021551065A1 (en) Fused ring compounds
MX2020001187A (es) Composiciones y métodos para la administración de virus adenoasociados.
PH12020500500A1 (en) Pyrazolopyrimidinone compounds and uses thereof
MX2019009255A (es) Proteínas quiméricas dirigidas y sus usos.
CY1122265T1 (el) Αντισωματα εναντι ταυ και χρησεις αυτων
MX2023002507A (es) Inhibidores de cd73.
EA201990400A1 (ru) Соединения и композиции и их применение
MX2019004859A (es) Tratamientos de combinacion que comprenden la administracion de imidazopirazinonas.
MX2019003805A (es) Activadores de flujo autofágico y fosfolipasa d y depuración de acumulaciones de proteína que incluyen tau y tratamiento de proteinopatías.
MX2019014292A (es) Anillos 5-5 fusionados como inhibidores c5a.
AU2018320418A1 (en) Pyridinamine-pyridone and pyrimidinamine-pyridone compounds
MX2020007628A (es) Composiciones y metodos de uso.
EA202090414A1 (ru) Соединения и их применение
PH12021550705A1 (en) Stable semaglutide compositions and uses thereof
PH12018502275A1 (en) Interferon beta antibodies and uses thereof
MX2019006495A (es) Tratamiento de enfermedades neurologicas.
NZ788133A (en) Cd73 inhibitors
WO2018183631A8 (en) Novel pharmaceutical formulations containing indirubin and derivatives thereof and methods of making and using the same
MX2020012281A (es) Composiciones que comprenden compuestos de bisfluoroalquil-1,4-ben zodiacepinona y metodos de uso de las mismas.
MX2018002446A (es) Compuestos heterociclicos fusionados como moduladores s1p.
AU2016348418A8 (en) Compositions comprising IL6R antibodies for the treatment of uveitis and macular edema and methods of using same
MX2020001855A (es) Composiciones farmacéuticas que contienen anticuerpos anti-beta-amiloides.
EA202192488A1 (ru) Антитела против tsg-6 и их применения
NZ756915A (en) Dual magl and faah inhibitors